Literature DB >> 8939151

Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic cat.

C M Counsell1, J F Bond, J L Ohman, J L Greenstein, R D Garman.   

Abstract

BACKGROUND: A heterodimeric acidic glycoprotein (Fel d 1) has been defined as the major allergen of the domestic cat. Because T-cell help is required for the initiation and maintenance of allergic responses, it is of importance to determine the T-cell-reactive regions of the Fel d 1 molecule.
METHODS: Overlapping peptides corresponding to the two chains of Fel d 1 were tested in proliferation assays on polyclonal T-cell lines and for the ability to bind Fel d 1-specific IgE in ELISA and histamine release assays.
RESULTS: Assay of T-cell lines derived from 53 subjects allergic to cats demonstrated that the majority of T-cell reactivity is found in chain 1 of Fel d 1. Two peptides (Fel-1 and Fel-2) containing major epitopes, alone or as a mixture, efficiently activated T cells and exhibited minimal detectable reactivity with IgE by ELISA or histamine release assay.
CONCLUSIONS: Two Fel d 1 peptides containing major T-cell epitopes have been identified, have been shown to bind minimal Fel d 1-specific IgE, and are now being tested for the ability to decrease T-cell responses in patients with cat allergy as a new form of immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8939151     DOI: 10.1016/s0091-6749(96)80004-2

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  12 in total

Review 1.  The potential of peptide immunotherapy in allergy and asthma.

Authors:  F Runa Ali; A Barry Kay; Mark Larché
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

Review 2.  Inhibition of human T-cell responses by allergen peptides.

Authors:  M Larché
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

3.  High-dose allergen exposure leads to tolerance.

Authors:  Judith A Woodfolk
Journal:  Clin Rev Allergy Immunol       Date:  2005-02       Impact factor: 8.667

4.  Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy.

Authors:  Anu K Immonen; Antti H Taivainen; Ale T O Närvänen; Tuure T Kinnunen; Soili A Saarelainen; Marja A Rytkönen-Nissinen; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-01       Impact factor: 7.397

5.  Direct ex vivo analysis of allergen-specific CD4+ T cells.

Authors:  William W Kwok; Michelle Roti; Jonathan H Delong; Venus Tan; Erik Wambre; Eddie A James; David Robinson
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

6.  "Venom" of the slow loris: sequence similarity of prosimian skin gland protein and Fel d 1 cat allergen.

Authors:  Sonja Krane; Yasuhiro Itagaki; Koji Nakanishi; Paul J Weldon
Journal:  Naturwissenschaften       Date:  2003-01-31

7.  Fel d 1-airway inflammation prevention and treatment by co-immunization vaccine via induction of CD4+CD25-Foxp3+ Treg cells.

Authors:  Yechun Pei; Shuang Geng; Lin Liu; Fengxiang Yan; Hong Guan; Jian Hou; Yongfu Chen; Bin Wang; Xiaorong An
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

8.  Application of proteases to the identification of chiral modifications in synthetic peptides.

Authors:  K M Keating
Journal:  J Biomol Tech       Date:  1999-06

9.  A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.

Authors:  Katarzyna Niespodziana; Margarete Focke-Tejkl; Birgit Linhart; Vera Civaj; Katharina Blatt; Peter Valent; Marianne van Hage; Hans Grönlund; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2011-03-16       Impact factor: 10.793

10.  In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity.

Authors:  Ola B Nilsson; Justus Adedoyin; Claudio Rhyner; Theresa Neimert-Andersson; Jeanette Grundström; Kurt D Berndt; Reto Crameri; Hans Grönlund
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.